mosliciguat

About Pulmovant

Pulmovant is a private, pre-revenue biotech company based in San Diego, established to address high unmet needs in pulmonary diseases. Its lead asset, mosliciguat, is a potential first-in-class, once-daily inhaled sGC activator currently in clinical development for PH-ILD, with a mechanism that may offer vasodilatory, anti-inflammatory, and anti-fibrotic benefits. The company operates under the Roivant Sciences umbrella, benefiting from its operational model and experienced leadership team, including CEO Drew Fromkin, to rapidly advance its pipeline. Pulmovant's strategy centers on creating a differentiated, inhaled treatment paradigm to improve outcomes for patients with challenging pulmonary conditions.

About Roivant Sciences

Roivant Sciences' mission is to improve health by rapidly delivering innovative medicines through its unique 'Vant' model—nimble, entrepreneurial subsidiaries. The company has demonstrated significant execution with 12 positive Phase 3 trials, 8 FDA approvals, and a successful commercial launch of VTAMA® for plaque psoriasis, which was subsequently acquired by Organon in 2024. Its strategy centers on decentralized decision-making, specialized expertise, and disciplined capital allocation to de-risk development and maximize value creation across a broad pipeline in autoimmune, pulmonary, and other diseases.

Therapeutic Areas

Other Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Drugs